Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers

Trial Profile

A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Sponsors mAbxience
  • Most Recent Events

    • 09 Aug 2021 Result (n=114) assessing pharmacokinetic equivalence in healthy male volunteers between MB02 and the reference bevacizumab, as well as comparable safety and immunogenicity profile, published in the British Journal of Clinical Pharmacology.
    • 07 Sep 2020 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top